




PHARMACEUTICAL 2017

ChemoCentryx Inc.
Rank 184 of 292





PHARMACEUTICAL 2017

ChemoCentryx Inc.
Rank 184 of 292



The relative strengths and weaknesses of ChemoCentryx Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ChemoCentryx Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 70% points. The greatest weakness of ChemoCentryx Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 96% points.

The company's Economic Capital Ratio, given in the ranking table, is 35%, being 32% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	148,691
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	38,335
Liabilities, Non-Current	101
Other Assets	6,276
Other Compr. Net Income	-10
Other Expenses	0
Other Liabilities	67,547
Other Net Income	757
Other Revenues	11,935
Property and Equipment	905
Research and Development	37,945
Selling, General and Administrative Expense	14,710

Output Variable	Value in 1000 USD
Assets	155,872
Liabilities	105,983
Expenses	52,655
Revenues	11,935
Stockholders Equity	49,889
Net Income	-39,963
Comprehensive Net Income	-39,968
Economic Capital Ratio	35%